Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Ascentage Pharma Group International ( (HK:6855) ) is now available.
Ascentage Pharma Group International announced the further grant of awards under its 2022 RSU Scheme, allocating 1,304,457 RSUs to 146 selected individuals, including directors and service providers. This move is part of the company’s strategy to incentivize its team and align their interests with long-term growth objectives, potentially enhancing its competitive positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:6855) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing novel therapies for cancer, hepatitis B, and age-related diseases. The company is known for its research and development efforts in drug development and clinical trials, aiming to address unmet medical needs in these areas.
Average Trading Volume: 2,389,582
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.46B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.